Vanja Z.
- Country
- Germany
- Department
- Clinic for Hematology and Oncology
Research Overview
- Phase I/II Study of QEL-005 Autologous CD19-Targeting CAR T-Regulatory Cell Therapy in Patients with Diffuse Cutaneous Systemic Sclerosis and Difficult-to-Treat Rheumatoid Arthritis
- Phase 3 Multicenter Randomized Open-Label Trial of Epcoritamab, Rituximab, and Lenalidomide Versus Chemoimmunotherapy in Untreated Follicular Lymphoma
- Phase III Randomized Trial of De-escalated MATRix Induction Therapy in Newly Diagnosed Primary CNS Lymphoma: Methotrexate, Cytarabine, Thiotepa, and Rituximab
Data & Insights
Has run more than one trial at 98 of 319 partner sites.
Specializations
Lymphoma Research
The investigator specializes in treating various forms of lymphoma, with particular emphasis on diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. Their research encompasses both previously untreated cases and relapsed/refractory disease states.
- Primary CNS Lymphoma
- Relapsed/Refractory DLBCL
- Novel Combination Therapies
A significant focus is placed on investigating innovative therapeutic combinations for lymphoma treatment, including targeted therapies and immunological approaches.
Hematologic Malignancies
The investigator conducts research in chronic lymphocytic leukemia (CLL), with particular attention to high-risk disease variants. Their work includes evaluation of novel therapeutic combinations and targeted treatment approaches.
- High-Risk CLL Management
- Genetic Risk Factor Assessment
- Novel Drug Combinations
Special attention is given to patients with specific genetic markers including 17p-deletion, TP53-mutation, and complex karyotype presentations.
Therapeutic Innovation
The investigator explores novel therapeutic combinations including targeted agents, monoclonal antibodies, and immunomodulatory drugs. Their research includes evaluation of treatments such as zilovertamab vedotin, epcoritamab, and tazemetostat.
- Immunotherapy Approaches
- Targeted Therapy Development
- Treatment Optimization
Research focuses on optimizing treatment responses while managing treatment-related events in various lymphoid malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.